Semax FDA Status: A Stroke Indication, Not a Nootropic Win

Current status: Semax is not FDA-approved, is not on the 503A bulk drug substances list, and no US pharmacy may legally compound it today. On July 24, 2026 an FDA advisory committee recommended adding it — non-bindingly, and for three neurological indications that have nothing to do with the reason most people buy Semax.

The vote

Semax was heard on day two of the July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. The committee recommended it for the section 503A bulks list by 8–5 in favor¹.

Semax drew the strongest favorable margin of the three substances heard on day two — Epitalon cleared 7–5 with one abstention, and emideltide (DSIP) was rejected 6–7¹. FDA has not published minutes, so the tallies come from trade press coverage and are attributed as such.

The indications FDA actually reviewed: cerebral ischemia, migraine, trigeminal neuralgia

FDA published the uses it evaluated for each substance ahead of the meeting. For Semax free base and Semax acetate, those uses were cerebral ischemia, migraine, and trigeminal neuralgia².

Read that against how Semax is sold. In the English-speaking market Semax is a nootropic — marketed for focus, motivation, memory, mental energy, "brain fog," and stacking with Selank. None of those uses was evaluated. Cognitive enhancement in healthy adults was not on the agenda, was not reviewed, and was not voted on.

The three indications FDA did review are serious clinical conditions: ischemic stroke, migraine, and a facial nerve pain disorder. They come from Semax's Russian clinical origin, where it has been used in stroke care and where the published trial literature sits³. That literature is what the nomination pointed to. It is not a body of work about a healthy person's productivity, and we walk through what it actually shows — and how thin the Western-standard evidence is — in Semax vs Selank.

"Approved in Russia" is not a US status

Semax attracts a particular kind of confusion because it genuinely is an approved medicine in another jurisdiction. That fact does real work in marketing copy and no work at all in US law.

A foreign marketing authorization does not make a substance an approved drug in the United States, does not satisfy the 503A conditions, and does not put anything on the FDA's list. It is also why the July vote was necessary in the first place: if Semax already had US standing, there would have been nothing to nominate.

Where a foreign authorization can matter is anti-doping. WADA's S0 class covers substances with no approval for human therapeutic use by any government health authority, so a substance approved somewhere is arguably outside S0 — but that is a narrow technical point, not a clearance, and other classes and the general prohibitions may still apply. Any tested athlete should check the current list and their sport's rules rather than reason from this paragraph; see the WADA 2026 prohibited list for peptides.

FDA's own reviewers recommended against

The agency's scientists opposed the entire slate of seven substances, describing missing human data, immunogenicity risk, peptide-related impurities, and a foundational difficulty in defining what these substances chemically are⁴. The committee — reconstituted weeks earlier with eight new members, most with ties to the peptide industry⁵ — voted the other way on six of seven.

What still has to happen

A favorable advisory vote lists nothing. Adding Semax to 21 CFR 216.23 requires FDA to publish a proposed rule, take public comment, and issue a final rule⁶. The list today contains six substances, none of them peptides⁶.

The only completed 503A bulks rulemaking took roughly three years — proposed rule December 2016, final rule effective March 21, 2019⁷. FDA has announced no timeline here; the "9 to 18 months" figure circulating online has no agency source.

What you should not conclude

• •Not that Semax is FDA approved or endorsed. 21 CFR 216.23(d) makes representing a compounded drug made from a listed bulk substance as "FDA approved, or otherwise endorsed by FDA generally or for a particular indication" a misbranding violation under sections 502(a) and/or 502(bb) of the Act⁶.
• •Not that the FDA reviewed Semax as a nootropic. It reviewed stroke-related brain injury, migraine and trigeminal neuralgia. A clinician could later prescribe a listed substance for other uses at their discretion, but that is a prescriber's call, not an agency finding about cognition in healthy people.
• •Not that nasal Semax products sold online are now legitimate. Any future listing would govern licensed pharmacies compounding against a prescription — not "research use only" material, which remains an unapproved drug. See where to buy peptides and research-chemical legality.
• •Not that the evidence changed. No trial was published in July; a committee voted.

Where Semax sits on FDA's lists today

Semax is not in FDA's live Category 2 table. It appears in the second table on that page — substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators," listed as "Semax (heptapeptide)"⁸. Withdrawn means the nomination was pulled. It is not a safety clearance and it does not make Semax compoundable.

The bottom line

Semax got the meeting's second-strongest favorable vote, 8–5, for cerebral ischemia, migraine and trigeminal neuralgia — three clinical neurology indications, none of them the cognitive-enhancement use that drives the market. FDA's reviewers opposed it. Nothing is listed, nothing is approved.

For the full meeting, read what actually happened at the FDA peptide advisory vote. For the category's legal status, are peptides legal?. For the science and the Selank comparison, see Semax vs Selank.